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Abstract
Survival in epithelial ovarian cancer (EOC) is influenced by the host immune response, yet the
key genetic determinants of inflammation and immunity that impact prognosis are not known. The
nuclear factor-kappa B (NF-κB) transcription factor family plays an important role in many
immune and inflammatory responses, including the response to cancer. We studied common
inherited variation in 210 genes in the NF-κB family in 10,084 patients with invasive EOC (5,248
high grade serous, 1,452 endometrioid, 795 clear cell, and 661 mucinous) from the Ovarian
Cancer Association Consortium. Associations between genotype and overall survival were
assessed using Cox regression for all patients and by major histology, adjusting for known
prognostic factors and correcting for multiple testing (threshold for statistical significance—p <
2.5×10−5). Results were statistically significant when assessed for patients of a single histology.
Key associations were with CARD11 (caspase recruitment domain family, member 11)
rs41324349 in patients with mucinous EOC (HR 1.82, 95% CI 1.41–2.35, p=4.13×10−6) and
TNFRSF13B (tumor necrosis factor receptor superfamily, member 13B) rs7501462 in patients
with endometrioid EOC (HR 0.68, 95% CI 0.56–0.82, p=2.33×10−5). Other associations of note
included TRAF2 (TNF receptor-associated factor 2) rs17250239 in patients with high-grade serous
EOC (HR 0.84, 95% CI 0.77–0.92, p=6.49×10−5) and PLCG1 (phospholipase C, gamma 1)
rs11696662 in patients with clear cell EOC (HR 0.43, 95% CI 0.26–0.73, p=4.56×10−4). These
associations highlight the potential importance of genes associated with host inflammation and
immunity in modulating clinical outcomes in distinct EOC histologies.
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INTRODUCTION
Epithelial ovarian cancer (EOC) is the sixth leading cause of cancer death among women in
developed countries (1), with a five-year survival rate of only 37% in the United States (2).
A key cause of poor survival is a lack of specific symptoms and screening methods; as such,
the majority of EOC patients present with distant spread of disease. A number of features in
addition to stage are known to impact clinical outcome, including age at diagnosis (3),
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extent of residual disease following initial cytoreductive surgery (optimal versus
suboptimal) (4), and baseline performance status (5). Genetic polymorphisms may also
influence EOC survival (6, 7). Understanding the totality of potential prognostic factors is
key to discerning pathogenic mechanisms that underlie carcinogenesis and progression in
EOC. Inflammation is known to play a role tumorigenesis (8); inflammation from multiple
causes, including talc use (9) and endometriosis (9, 10), and the presence of non-specific
inflammatory markers such as C-reactive protein (CRP) are associated with increased EOC
risk (11). Furthermore, the presence of an ongoing inflammatory response, measured by
CRP and hypoalbuminemia, has been shown to independently predict poor prognosis in
advanced EOC (12).
The nuclear factor-kappa B (NF-κB) family of transcription factors regulates the
transcription of multiple proteins, including cytokines, chemokines, acute phase reactants,
complement factors, adhesion molecules, and other proteins involved in inflammation,
apoptosis, and cell division (13). In canonical NF-κB signaling, binding of NF-κB-
associated receptors leads to phosphorylation and activation of the inhibitor of kappa B
kinase (IKK) complex, which leads to phosphorylation and proteosomal degradation of the
inhibitor of kappa B (IκB), thus releasing NF-κB transcription factors into the nucleus to
regulate gene transcription (14). Alternatively, receptor binding and IKK activation can lead
to processing of the p100 protein into active p52, which binds the NF-κB family member
Rel-B, translocates to the nucleus, and regulates gene transcription (14). To assess the role
of genetic variation in NF-κB signaling on EOC survival, we evaluated common inherited
single nucleotide polymorphisms (SNPs) in key genes which mediate NF-κB activation,
inhibit NF-κB function, assist degradation, or regulate nuclear function among patients from
the Ovarian Cancer Association Consortium (OCAC).
MATERIALS AND METHODS
Study Participants
A total of 10,084 women with invasive EOC (37,171 person-years follow-up) and greater
than 90% estimated European ancestry were analyzed as described previously (15, 16).
Participants were from 28 OCAC studies (Supplemental Table 1) based in Europe, North
America, and Australia which conducted follow-up for vital status, including 12 studies
(AUS, BAV, HAW, HSK, LAX, MAL, MAY, NCO, NEC, ORE, PVD, and SRO) followed
for disease recurrence or progression.
SNP Selection
We identified 210 key genes (Supplemental Table 2) known to encode NF-κB subunits or
molecules key to NF-κB activation (in signaling cascade), inhibition (inhibitory role),
degradation (involved in proteasomal degradation), and nuclear function (nuclear proteins
involved in transcription) (6). TagSNPs within 5 kb based on r2 ≥0.8, minor allele frequency
(MAF) ≥0.05 in Europeans were identified using the most informative source for each gene
from among HapMap Phase II Release 24 (http://www.hapmap.org), the 1000 Genomes
Project Low-Coverage Pilot (http://www.1000genomes.org/), SeattleSNPs (http://
pga.mbt.washington.edu/), Innate Immunity PGA (http://innateimmunity.net/), and NIEHS
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SNPs (http://egp.gs.washington.edu) (17). Additional putative-functional SNPs were also
included, regardless of linkage disequilibrium (LD), with European MAF ≥0.05 which were
1 kb upstream, non-synonymous, or resided in a 3′ untranslated region (UTR), 5′ UTR,
splice site, or miRNA binding site (http://www.microrna.org/microrna/home.do, http://
www.targetscan.org/). Finally, SNPs with an Illumina design score <0.4 or in LD (r2>0.80)
with a SNP found to be null (p >0.05) in a small prior analysis (16) were excluded. With this
approach, 76% of significant SNPs with MAF ≥ 0.05 were adequately tagged if we used
HapMap as our reference.
Genotyping and Quality Control
Germline genotyping was conducted using an Illumina Infinium iSelect BeadChip as part of
the Collaborative Oncological Gene-environment Study (COGS) (16). Centralized
genotyping used raw intensity data files and a cluster file generated with HapMap2
European, African, and Asian samples. Samples were excluded with 1) conversion rate
<95%, 2) heterozygosity > five standard deviations from the European mean heterozygosity,
3) ambiguous sex, 4) lowest call rate from an observed first-degree relative pair, or 5)
duplicate samples that were non-concordant for genotype or genotypic duplicates that were
not concordant for phenotype. SNPs were excluded with 1) no genotype call, 2)
monomorphism, 3) call rate <95% with MAF >0.05 or call rate <99% with MAF <0.05, 4)
deviation from Hardy-Weinberg equilibrium (p <10−7), or 5) >2% duplicate discordance.
SNP Imputation
Imputation to the 1000 Genomes (1000G) Phase I Integrated Release Version 3 haplotypes
was carried out in MaCH (18) using all 1,092 1000G samples and excluding monomorphic
and singleton sites.
Statistical Methods
HapMap2 genotypes were used to define intercontinental ancestry; among Europeans (>90%
European ancestry), we used 37,000 unlinked non-NF-κB markers in population
stratification principal components (PC) analysis (16). Cox regression accounting for left
truncation and right censoring at 10 years estimated hazard ratios (HRs) and 95% confidence
intervals (CIs) for association with overall survival, defined as time to death from any cause.
Censoring at 10 years was performed to minimize competing causes of mortality, which
become more common after 10 years from EOC diagnosis. HRs were calculated based on
the ordinal number of copies of the minor allele for all genotyped SNPs and allele dosage
variables for all imputed SNPs. Analyses were conducted overall and within the four most
common histologic subtypes (high grade serous, mucinous, endometrioid, and clear cell).
Analyses adjusted for study site and the first five population substructure PCs, as well as the
following covariates which associated with survival in these data (p <0.05, Supplemental
Table 3): age (continuous), tumor stage summarized from FIGO or SEER stage (localized,
regional, distant), tumor grade (well, moderately, poorly, or undifferentiated), oral
contraceptive use (ever, never), and, for analysis of all cases only, histology (serous,
mucinous, endometrioid, clear cell, mixed cell, undifferentiated, unknown). Sensitivity
analyses included covariates only for age, five population substructure PCs, and study site.
Analyses were also conducted with a recurrence endpoint defined as time to disease
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recurrence or death (377 additional events), among cases which were optimally debulked in
cytoreductive surgery (2,078 cases having no residual deposits of cancer that were >1 cm)
and among cases where surgical debulking was suboptimal (1,215 cases with >1 cm residual
disease).
To address multiple testing concerns, we used spectral decomposition of the observed
genotype matrix (19) to account for observed LD and estimated that the effective number of
independent tests for each analysis was 2,000. As a result, only SNPs with p-values
<2.50×10−5 (0.05/2,000) were considered statistically significant. We used SAS (SAS
Institute, Inc., Cary, NC) and R (R Foundation for Statistical Computing, Vienna, Austria),
and, in regions of interest, LocusZoom (Standalone Version) (20) and Haploreg v2 (21) for
plotting and annotation respectively.
RESULTS
We analyzed 2,254 SNPs in 210 genes for clinical outcome among 10,084 EOC cases. The
strongest survival association in any of the histology subgroups was seen in 661 mucinous
EOC with the CARD11 intronic SNP rs41324349 (HR =1.82, p =4.13×10−6, Table 1). In
addition, five of the fifty-six genotyped CARD11 SNPs were associated at p <0.005,
including two independent SNPs (r2 <0.20) with p <0.001 (Table 1). The distribution of p-
values and correlation with rs41324349 across CARD11 are shown in Figure 1 for both
directly genotyped and imputed SNPs. Imputation revealed that the CARD11 SNP
rs2527513, which was in strong LD with rs41324349, was highly correlated with survival.
For 1,452 patients with endometrioid EOC, the TNFRSF13B 3′ UTR SNP rs7501462
showed the strongest association (HR =0.68, p =2.33×10−5). Out of eighteen additional
TNFRSF13B SNPs, two others (rs7212800 and rs11078362) showed association (p <0.005)
in endometrioid EOC patients; these additional SNPs were in moderate LD with rs7501462
(r2 =0.26 and r2 =0.76, respectively).
For 5,248 high grade serous EOC patients, the TRAF2 SNP rs17250239 showed the most
significant association (HR =0.84, p =6.49×10−5), although this was just beyond our
pathway-wide threshold for statistical significance (p <2.50×10−5). The rs17250239 SNP is
located in an intronic sequence within the TRAF2 gene. In 795 clear cell EOC patients,
PLCG1 rs11696662 showed the most significant association (HR = 0.43, p = 4.56 × 10−4),
but this was not within our pathway-wide threshold for statistical significance. Finally,
among all cases, the SNPs rs61764220 and rs518162 (within the genes MAPK3 and PGR,
respectively) had the strongest survival associations (HR =0.81, p =6.50×10−4, and HR
=0.87, p =8.11×10−4, respectively, Table 1). However, these results did not meet our
threshold for statistical significance taking into account multiple comparisons (p
<2.50×10−5), and so there were not clear associations between polymorphisms in MAPK3
and PGR and survival in EOC.
In addition to OS, we performed sensitivity analyses for time to recurrence, examined results
from minimally adjusted analyses, and assessed optimally debulked and suboptimally
debulked patients separately. The HRs for recurrence were similar to HRs for survival with
and without full covariate adjustment for each of the SNPs that we had considered to have
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the most significant associations with survival (p < 0.0001) and among optimally debulked
compared to suboptimally debulked patients (available on one-third of participants; data not
shown).
DISCUSSION
In this pooled analysis of over 10,000 EOC patients enrolled in 28 different studies within
OCAC, we evaluated associations between NF-κB-related SNPs with survival. We did not
identify SNPs associating with overall survival among all EOC patients that met our
corrected threshold for statistical significance. However, we identified three SNPs,
rs41324349, rs2527513, and rs7501462, which associated with overall survival and time to
recurrence for EOC subtypes accounting for known prognostic factors. The CARD11
intronic SNPs rs41324349 and rs2527513 were in high LD with each other and were
associated with shortened survival in patients with mucinous EOC, whereas TNFRSF13B 3′
UTR rs7501462 associated with improved outcome among patients with endometrioid EOC.
Sensitivity analyses showed concordance between HRs for overall survival and time to
recurrence, and among optimally debulked patients.
CARD11, also known as Carma 1, is an adapter protein that functions as a molecular
scaffold in leukocytes (22). CARD11 interacts with the pro-apoptotic protein BCL10, and
overexpression of CARD11 leads to increased NF-κB activation (23). Oncogenic mutations
in CARD11 have been reported in association with several types of lymphoma (24). The
expression of CARD11 in leukocytes suggests that it may influence immune/inflammatory
responses to EOC. rs41324349 lies within seven regulatory motifs that would be altered by
the base change, which could potentially alter transcription; however, this SNP is not in a
conserved domain. Six additional intronic and one synonymous SNPs located in regulatory
motifs were correlated with this SNP (r2 ≥0.6). Primary mucinous EOC is relatively
uncommon, and mechanisms responsible for tumorigenesis, invasion, and metastasis that are
specific for mucinous subtype have not yet been clearly demonstrated. Thus, it is not clear
how a change in expression or function of CARD11 would impact survival specifically in
this subgroup.
TNFRSF13B, more commonly known as TACI (transmembrane activator and calcium-
modulating cyclophilin ligand interactor), is a member of the tumor necrosis factor (TNF)
receptor superfamily and is found on B lymphocytes (25). TACI interacts with the TNF
family members BAFF (B cell activating factor) and APRIL (a proliferation-inducing
ligand) to activate NF-κB and other transcription factors in B cells. It is not known whether
rs7501462 affects TNFRSF13B expression, and it is not located in an evolutionarily
conserved domain; however, it falls in a strong enhancer region and POL2 binding site in B-
lymphoblastoid cell lines. As the primary pathologic process associated with endometrioid
ovarian carcinomas is endometriosis, alterations in TNFRSF13B that affect inflammatory
responses to endometriosis may modulate the aggressiveness of endometriosis-associated
carcinomas.
Interestingly, while SNPs associated with survival were identified for relatively rare
histologies (mucinous and endometrioid histologies), there were no SNP associations
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identified for the most common EOC histology (high grade serous). This may simply reflect
underdetection of SNPs due to a relatively stringent statistical threshold for significance, as
there were several SNPs, most notably rs17250239 (HR =0.84, p =6.49×10−5) which had
survival associations not quite meeting our pre-specified threshold for significance (p <
2.5×10−5). However, this may also reflect that survival high grade serous EOC, which is
characterized by dramatic alterations in DNA macrostructure, may be more closely
associated with certain amplified or deleted regions of DNA rather than alterations at the
single nucleotide level.
The search for inherited variants associated with EOC outcome has proven challenging, with
no published variants reaching genome-wide significance to date (15, 26). Here, by testing a
candidate pathway within a consortium, we identified two SNPs from NF-κB-related genes
that associated with survival in patients with distinct histologic subtypes of EOC using a
pathway-wide statistical significance threshold. Strengths of this report include large sample
size and use of centralized genotyping; limitations include missing data on surgical
debulking status. For example, analysis by debulking status classified patients based on
whether <1 cm or ≥1 cm residual disease was present, as opposed to complete debulking (no
visible residual disease); thus, association in certain patient subsets may have been
overlooked. In addition, for some population-based studies, there was possible over-
enrollment of women with longer survival; this could also bias results to the null if NF-κB
SNPs associate only with very poor survival time.
As additional outcome-associated variants come to light, further work will address the
potential prognostic utility of a broad panel of outcome-associated SNPs. For now, we
provide evidence that the genetics of the immune/inflammatory response to EOC may
impact clinical outcome and suggest that characterization of functional mechanisms will be
a key next step to understanding this deadly disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Strength of association between CARD11 genotypes and survival of women with
mucinous EOC (N=661)
Adjusted for study site, first five European ancestry population substructure PCs, age at
diagnosis, tumor stage, tumor grade, and oral contraceptive use. Circles represent imputed
SNPs, while triangles represent genotyped SNPs.
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Table 1
SNP association with EOC overall survival (p<0.001, r2<0.20)
Histologic Subtype Gene SNP Alleles MAF HR (95% CI) p-value
Mucinous (N=661) CARD11 rs41324349 C>A 0.44 1.82 (1.41–2.35) 4.13 × 10−6
rs6944821 A>G 0.31 1.64 (1.26–2.13) 2.47 × 10−4
rs34251392 A>G 0.34 0.63 (0.48–0.82) 5.08 × 10−4
TRAF5 rs79776636 G>C 0.04 2.89 (1.70–4.92) 4.01 × 10−4
IKBKE rs10836 G>C 0.47 0.62 (0.47–0.82) 6.04 × 10−4
PIK3R1 rs10940158 G>A 0.52 1.47 (1.17–1.85) 8.47 × 10−4
Endometrioid (N=1,452) TNFRSF13B rs7501462 A>G 0.26 0.68 (0.56–0.82) 2.33 × 10−5
PELI2 rs1152468 G>C 0.40 0.75 (0.64–0.87) 1.86 × 10−4
MAP2K6 rs72847071 G>A 0.09 1.61 (1.26–2.05) 2.66 × 10−4
IL3 rs40401 G>A 0.22 0.72 (0.59–0.87) 5.65 × 10−4
TLR5 rs5744157 G>C 0.12 0.66 (0.52–0.85) 8.28 × 10−4
High grade serous (N=5,248) TRAF2 rs17250239 G>A 0.11 0.84 (0.77–0.92) 6.49 × 10−5
PRKCA rs9894564 A>G 0.24 0.90 (0.84–0.95) 5.83 × 10−4
Clear cell (N=795) PLCG1 rs11696662 G>A 0.07 0.43 (0.26–0.73) 4.56 × 10−4
MAPK1 rs72847071 T>A 0.43 0.70 (0.57–0.86) 6.10 × 10−4
All (N=10,084) MAPK3 rs61764220 A>G 0.03 0.81 (0.71–0.92) 6.50 × 10−4
PGR rs518162 G>A 0.08 0.87 (0.81–0.95) 8.11 × 10−4
Bold indicates p< 2.5×10−5; adjusted for study site, first five European ancestry population substructure PCs, age at diagnosis, tumor stage, tumor
grade, oral contraceptive use, and histology (for analyses of all cases only); SNPs with p<0.001, but correlated at r2>0.20 SNPs above are not
shown; SNP id is dbSNP 137 rsid; MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval; minor allele designation based on allele
frequencies in all cases.
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